• Canagliflozin Reshapes Mitochondria in Diabetic Kidneys

  2026-08-24

  The reference study shows that Canagliflozin improves mitochondrial architecture and bioenergetics in proximal tubular cells from hypertensive–diabetic mice, with stronger functional effects in males than females. These findings extend the interpretation of SGLT2 inhibition beyond glucose lowering and identify mitochondrial remodeling as a potential component of renal protection.

• Anagliptin Assay Design for Vascular Research

  2026-08-24

  Anagliptin (SK-0403) is more than a DPP-4 inhibitor in vascular experiments. This guide shows how to separate incretin pharmacology from direct smooth-muscle effects and design mechanistically informative rabbit-aorta assays.

• From S-Phase Signal to Vascular Mechanism

  2026-08-23

  A translational framework for using EdU-based flow cytometry to connect DNA synthesis with endothelial–smooth muscle crosstalk, hypoxia pulmonary hypertension, genotoxicity testing, and pharmacodynamic decision-making.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-08-22

  The reference study identifies circulating moesin (MSN) as a severity-associated biomarker of endothelial injury in sepsis and links its elevation to Rock1/MLC and NF-κB signaling. By combining patient measurements, mouse models, and endothelial-cell experiments, the work connects clinical association with a plausible mechanism of vascular barrier disruption.

• Exo1 in Exocytosis Assay Design

  2026-08-22

  Exo1 enables acute, mechanistically distinct membrane trafficking inhibition for Golgi–ER transport, ARF1 biology, and exocytosis assays. Used with appropriate controls, it can also help separate secretion-dependent effects from tumor extracellular vesicle behavior without being misrepresented as a direct or clinically validated metastasis therapy.

• OSMI-1: O-GlcNAc Transferase Inhibitor Guide

  2026-08-21

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor that reduces protein O-GlcNAcylation through OGT inhibition. Its reported biochemical potency, cellular viability effect, zebrafish acute-toxicity benchmarks, and formulation limits support controlled mechanistic research rather than direct therapeutic interpretation.

• Cimetidine in BBB and H2R Research Workflows

  2026-08-20

  Cimetidine supports a practical two-track workflow: mechanistic H2 receptor studies in gastrointestinal cancer models and controlled transport testing in surrogate blood-brain barrier assays. Its documented solubility and distinct pharmacological profile make it useful for assay development, provided permeability, recovery, and receptor effects are interpreted separately.

• Temozolomide Workflows for ATRX-Deficient Glioma

  2026-08-20

  Build reproducible Temozolomide assays around DNA damage, ATRX status, and rational RTK or PDGFR inhibitor combinations. This guide emphasizes reagent handling, dose–time design, genotype-aware controls, and troubleshooting for translational glioma research.

• Hesperadin: Aurora B Kinase Inhibitor Guide

  2026-08-19

  Hesperadin is an ATP-competitive Aurora B kinase inhibitor that disrupts histone H3 Ser-10 phosphorylation and mitotic chromosome behavior. Its biochemical potency, HeLa-cell phenotype, solvent profile, and checkpoint relevance make it a useful research tool rather than a clinical treatment claim.

• CH 223191 Workflows for AhR Mechanistic Studies

  2026-08-19

  CH 223191 enables controlled interrogation of AhR activity across dioxin toxicology, epithelial differentiation, and microbiota-linked intestinal repair models. This practical workflow connects concentration planning, CYP1A1 readouts, organoid assays, and troubleshooting for reproducible environmental toxicology research.

• Adefovir: From HBV Assays to Renal Risk

  2026-08-18

  Adefovir and GS-0393 offer a powerful model for studying HBV DNA polymerase inhibition and OAT1-mediated renal handling. This article connects antiviral assay design with a clinically important, evidence-based framework for detecting phosphate-wasting toxicity and interpreting translational exposure.

• Canagliflozin: SGLT2 Inhibitor Research Guide

  2026-08-18

  Canagliflozin is a selective SGLT2 inhibitor that suppresses renal glucose reabsorption and increases urinary glucose excretion. Recent mouse data link treatment with proximal tubular mitochondrial remodeling, improved bioenergetics in males, and reduced albuminuria.

• A20, Oxidized DNA, and Acute Kidney Injury

  2026-08-17

  The reference study identifies oxidized self-DNA as an inflammatory driver in acute kidney injury and shows that A20 limits this response by restraining STING signaling and NLRP3-mediated pyroptosis. Its mechanistic and peptide-validation data position the A20–NEK7 interaction as a potential therapeutic entry point, while also providing a framework for interpreting inflammasome modulation in related disease models.

• Berberine Hydrochloride: AMPK Research Workflows

  2026-08-17

  Berberine hydrochloride is a defined chemical probe for connecting AMPK-driven metabolic regulation with LDL receptor, mitochondrial, oxidative-stress, and cancer readouts. This workflow shows how to move from reproducible DMSO stocks to cell-based assays, cardiotoxicity models, and troubleshooting decisions without overextending evidence from botanical extracts.

• Sitagliptin Phosphate Monohydrate in Gut Signaling

  2026-08-16

  Sitagliptin phosphate monohydrate is a selective DPP-4 inhibitor that can help separate incretin-dependent glucose regulation from intestinal stretch signaling. This article translates recent gut mechanosensation findings into practical assay and study-design decisions.

8026 records 1/536 page Next 12345 下5页 Last page